– LIDDS publishes Annual Report for 2020
The Annual Report is attached to this press release and alos available on LIDDS website: https://liddspharma.com/investors/#financial-reports.
For more information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 [email protected]
LIDDS AB is required to disclose this information pursuant to
Nasdaq First North Growth Market – Rulebook
. The information was submitted for publication, through the agency of the aforementioned contact person, on April 16, 2021 at 15:00 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical ph
Investegate |LIDDS AB Announcements | LIDDS AB: Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
LIDDS AB: Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(0)
UPPSALA, SWEDEN - LIDDS AB (publ) announced today that the journal
International Journal of Pharmaceutics has accepted a biomolecule study from LIDDS for publication. The investigation has been performed in collaboration with the Karolinska Institute in Huddinge, Sweden and Truly labs in Lund, Sweden. The study confirms that proteins are released from NanoZolid depots with maintained bio-functionality, illustrated by protein targeting to tumor cell receptors. The investigation was performed with fluorescence-imaging.
The NanoZolid technology has during the last years been shown to enable a controlled release of a wide range of drugs following a single injection, resulting in stable and pharmacologically validated effects over a desired time period. In this study, a fluorescence-labelled model substance, Epidermal Growth Factor (EGF) protein, was used and followed longitudinally in mice after subcutaneous injections of the NanoZolid depot implants. The labelled EGF accumulated
International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the journal
International Journal of Pharmaceutics has accepted a biomolecule study from LIDDS for publication. The investigation has been performed in collaboration with the Karolinska Institute in Huddinge, Sweden and Truly labs in Lund, Sweden. The study confirms that proteins are released from NanoZolid® depots with maintained bio-functionality, illustrated by protein targeting to tumor cell receptors. The investigation was performed with fluorescence-imaging.
The NanoZolid® technology has during the last years been shown to enable a controlled release of a wide range of drugs following a single injection, resulting in stable and pharmacologically validated effects over a desired time period. In th